



A Step Towards Personalized Medicine: Seeing What's Unseen, Making Clinically Actionable Decisions

Real-world evidence, as published in *The Multiple Sclerosis Journal – Experimental, Translation and Clinical*, confirms the Octave MSDA test's impact on guiding treatment decisions.

About this study

Real-World Clinical Utility of a Multi-Protein Blood-Based Biomarker Assay for Disease Activity Assessments in Multiple Sclerosis, this study demonstrated the clinical utility of the MSDA Test in enhancing confidence and informing MS treatment decisions when used alongside the standard of care.

69.2%

of the time treating clinicians agreed or strongly agreed that **longitudinal MSDA** results influenced their decision making

59.8%

of the time treating clinicians agreed or strongly agreed that a **single MSDA** result had an impact on their decision making

1 in 5

time points, clinicians **changed** their clinical decision based on the results of an MSDA Test

Study design

INCLUSION CRITERIA

Patients aged 18 to 99 with a documented diagnosis of MS, CIS, or RIS, and at least 2 MSDA tests from routine clinical care between March 1st, 2022 and January 8th, 2024.

GENDER DISTRIBUTION

78.1% FEMALE,
21.9% MALE




EXCLUSION CRITERIA

Patients with incomplete data, pregnant or up to 6 weeks postpartum, or a major unrelated illness or comorbidity that affected MS management.

PATIENT AGE

AVERAGE
AGE 50



CLINICIAN POPULATION



20 CLINICIANS, ACROSS 14 CLINICS

CHARTS REVIEWED



352 CHARTS REVIEWED




FIGURE 1

Why The MSDA Test Matters: Clinical Utility Study Findings

KEY FINDING #1

Clinicians' confidence in the MSDA test grows with longitudinal use.

Prompt: Single MSDA test results influenced the decision to continue or change the MS management of this patient at this time.




Figure 3: Clinician-reported influence of a single MSDA test to continue or change the MS management of a patient.

Prompt: The change (or stability) across multiple MSDA test results influenced the decision to continue or change the MS management of this patient.




Figure 3: Clinician-reported influence of multiple MSDA tests to continue or change the MS management of a patient.

KEY FINDING #2

~1 in 5 decision time points, clinicians changed their treatment plan.

What was the recommended treatment plan before MSDA?




Figure 4: Paired pre/post MSDA decision impact responses for up to 3 MSDA tests per patient chart reviewed.

KEY FINDING #3

Identified 3 use cases where the MSDA test informed decision making.




Figure 5: Relationships between MSDA scores and post-MSDA decisions from study site staff chart review.